Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Lab-Made antibody disarm a stubborn lung infection?

NCT ID NCT07774403

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial tests an experimental drug called AZD0292 in adults with bronchiectasis who have a chronic Pseudomonas aeruginosa infection in their lungs. The goal is to see if the drug, given by IV infusion, can reduce the number of moderate-to-severe lung flare-ups (exacerbations) compared to a placebo. About 84 participants will be randomly assigned to receive either AZD0292 or a placebo, and researchers will track flare-ups over time. The study also looks at safety and how the drug affects quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD0292, an experimental antibody given by IV infusion
What this could lead to
If effective, AZD0292 could offer a new way to reduce severe lung infections and flare-ups in people with bronchiectasis who carry Pseudomonas bacteria.
What could go wrong
This is an early-phase study with a small number of participants, so results may not hold up in larger trials. The drug may also cause side effects or fail to reduce exacerbations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 84 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be ≥ 18 years of age at the time of signing the informed consent/assent. * Weight ≥ 35 kg. * Bronchiectasis diagnosed by a physician and confirmed by CT demonstrating abnormal bronchial dilation in ≥ 1 lobe. Note: A historical CT scan within the past 5 years is acceptable. If not available, a CT scan should be conducted at screening to confirm eligibility. * Participants who are receiving appropriate standard of care therapy per local guidelines and have a documented history of ≥ 2 moderate exacerbations or ≥ 1 severe exacerbation in the preceding 12 months requiring antibiotics * Participants who are clinically stable and free from an exacerbation of bronchiectasis for 4 weeks prior to randomization * Participants with pre- or post-bronchodilator FEV1 ≥ 25% predicted value at screening. * Presence of positive (PCR or culture) PsA in an airway sample at least once in the last 24 months prior to screening * Presence of culture positive PsA in sputum at least within 5 weeks of randomization. Participants who have previously received PsA eradication therapy, as determined appropriate by their treating provider, but remain colonized with PsA are eligible for the study. * Capable of giving signed informed consent/assent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol Exclusion Criteria: * Primary lung diagnosis other than bronchiectasis * Evidence of active tuberculosis or active nontuberculous mycobacteria being treated or requiring treatment. Participants currently receiving treatment for active TB or nontuberculous mycobacteria may be considered after completion of an appropriate course of therapy * Evidence of an active allergic bronchopulmonary aspergillosis being treated or requiring treatment * Need for long term supplemental oxygen. Oxygen use for ambulation and relief of breathlessness after exercise is allowed * Malignancy, current or within the previous 5 years, except for stable prostate cancer, adequately treated non-invasive basal cell and squamous cell carcinoma of the skin and cervical carcinoma in situ treated with apparent success more than one year prior to enrolment * AIDS or Advanced human immunodeficiency virus disease (CD4 count of \< 200 cells/mm3) * History of severe adverse reaction associated with a mAb, and/or history of severe allergic reaction (eg, anaphylaxis that required the use of epinephrine/adrenaline or hospitalization), and/or history of immune complex disease (Type III hypersensitivity reactions) to monoclonal antibody administration * Treatment with long term anti-PsA antibiotics, macrolides, or DPP-1 inhibitors, which are newly initiated within the 3 months prior to screening * Chronic immunosuppressive therapy (including prednisolone \> 5 mg or equivalent) newly initiated within the last 3 months * Receipt of investigational products indicated for the treatment or prevention of bronchiectasis exacerbations or expected receipt during the study * Participation with a study intervention used within the last 30 days or 5 half-lives of the investigational product from the other clinical study, whichever is longer, prior to screening. * Female participants who are pregnant, lactating, or WOCBP and not using a highly effective method of contraception or abstinence from at least 4 weeks prior to study intervention administration and until at least 6 months after study intervention administration

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bronchiectasis with pseudomonas aeruginosa colonization are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bronchiectasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bronchiectasis with pseudomonas aeruginosa colonization

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    40 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Anyang, 455099, China

  • Research Site

    RECRUITING

    Beijing, 100020, China

  • Research Site

    RECRUITING

    Beijing, 100034, China

  • Research Site

    NOT_YET_RECRUITING

    Beijing, 100730, China

  • Research Site

    NOT_YET_RECRUITING

    Changsha, 410005, China

  • Research Site

    RECRUITING

    Chengdu, 610014, China

  • Research Site

    RECRUITING

    Chengdu, 610078, China

  • Research Site

    RECRUITING

    Chengdu, 611130, China

  • Research Site

    RECRUITING

    Chizhou, 247099, China

  • Research Site

    RECRUITING

    Haikou, 570311, China

  • Research Site

    RECRUITING

    Hefei, 230061, China

  • Research Site

    NOT_YET_RECRUITING

    Hohhot, 010010, China

  • Research Site

    RECRUITING

    Hohhot, 010050, China

  • Research Site

    RECRUITING

    Jinan, 250013, China

  • Research Site

    RECRUITING

    Jinhua, 321000, China

  • Research Site

    NOT_YET_RECRUITING

    Jining, 272006, China

  • Research Site

    RECRUITING

    Kunming, 650032, China

  • Research Site

    RECRUITING

    Langfang, 065000, China

  • Research Site

    RECRUITING

    Linhai, 317000, China

  • Research Site

    RECRUITING

    Liuzhou, 545006, China

  • Research Site

    RECRUITING

    Nanchang, 330000, China

  • Research Site

    RECRUITING

    Nanchang, 330006, China

  • Research Site

    RECRUITING

    Nanning, 530021, China

  • Research Site

    RECRUITING

    Shanghai, 200032, China

  • Research Site

    RECRUITING

    Shanghai, 200065, China

  • Research Site

    NOT_YET_RECRUITING

    Shanghai, 200080, China

  • Research Site

    RECRUITING

    Shanghai, 200240, China

  • Research Site

    RECRUITING

    Shanghai, 201199, China

  • Research Site

    NOT_YET_RECRUITING

    Shenyang, 110004, China

  • Research Site

    RECRUITING

    Taicang, 215400, China

  • Research Site

    RECRUITING

    Taizhou, 318000, China

  • Research Site

    RECRUITING

    Wenzhou, 325000, China

  • Research Site

    RECRUITING

    Xinxiang, 453100, China

  • Research Site

    RECRUITING

    Xuzhou, 221000, China

  • Research Site

    RECRUITING

    Zaozhuang, 277102, China

  • Research Site

    RECRUITING

    Zhangzhou, 363099, China

  • Research Site

    NOT_YET_RECRUITING

    Zhengzhou, 450000, China

  • Research Site

    RECRUITING

    Zhengzhou, 450006, China

  • Research Site

    RECRUITING

    Zhuzhou, 412007, China

  • Research Site

    RECRUITING

    Zibo, 255036, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.